Möpert Kristin, Hajek Petr, Frank Stephan, Chen Christiane, Kaufmann Jörg, Santel Ansgar
Silence Therapeutics AG, 13125 Berlin, Germany.
Exp Cell Res. 2009 Aug 1;315(13):2165-80. doi: 10.1016/j.yexcr.2009.04.016. Epub 2009 May 3.
RNAi mediated loss of Drp1 function changes mitochondrial morphology in cultured HeLa and HUVEC cells by shifting the balance of mitochondrial fission and fusion towards unopposed fusion. Over time, inhibition of Drp1 expression results in the formation of a highly branched mitochondrial network along with "bulge"-like structures. These changes in mitochondrial morphology are accompanied by a reduction in levels of Mitofusin 1 (Mfn1) and 2 (Mfn2) and a modified proteolytic processing of OPA1 isoforms, resulting in the inhibition of cell proliferation. In addition, our data imply that bulge formation is driven by Mfn1 action along with particular proteolytic short-OPA1 (s-OPA1) variants: Loss of Mfn2 in the absence of Drp1 results in an increase of Mfn1 levels along with processed s-OPA1-isoforms, thereby enhancing continuous "fusion" and bulge formation. Moreover, bulge formation might reflect s-OPA1 mitochondrial membrane remodeling activity, resulting in the compartmentalization of cytochrome c deposits. The proteins Yme1L and PHB2 appeared not associated with the observed enhanced OPA1 proteolysis upon RNAi of Drp1, suggesting the existence of other OPA1 processing controlling proteins. Taken together, Drp1 appears to affect the activity of the mitochondrial fusion machinery by unbalancing the protein levels of mitofusins and OPA1.
RNA干扰介导的动力相关蛋白1(Drp1)功能丧失通过使线粒体分裂与融合的平衡向无对抗的融合方向转变,从而改变培养的人宫颈癌细胞(HeLa)和人脐静脉内皮细胞(HUVEC)中的线粒体形态。随着时间的推移,抑制Drp1表达会导致形成高度分支的线粒体网络以及“凸起”样结构。线粒体形态的这些变化伴随着线粒体融合蛋白1(Mfn1)和2(Mfn2)水平的降低以及视神经萎缩蛋白1(OPA1)亚型的蛋白水解加工改变,并导致细胞增殖受到抑制。此外,我们的数据表明,凸起的形成是由Mfn1的作用以及特定的蛋白水解短型OPA1(s-OPA1)变体驱动的:在缺乏Drp1的情况下Mfn2的缺失会导致Mfn1水平以及加工后的s-OPA1亚型增加,从而增强持续的“融合”和凸起形成。此外,凸起的形成可能反映了s-OPA1的线粒体膜重塑活性,导致细胞色素c沉积物的区室化。在对Drp1进行RNA干扰后,Yme1L和线粒体内膜组织蛋白酶B2(PHB2)蛋白似乎与观察到的OPA1蛋白水解增强无关,这表明存在其他控制OPA1加工的蛋白。综上所述,Drp1似乎通过使线粒体融合蛋白和OPA1的蛋白质水平失衡来影响线粒体融合机制的活性。